Terminated × Hodgkin Disease × Other hematologic neoplasm × Clear all
NCT03246906 2025-06-04

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Terminated
150 enrolled
NCT01998035 2024-08-22

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
58 enrolled 11 charts
NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Pfizer

Phase 1 Terminated
249 enrolled 43 charts
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT00057954 2023-06-28

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Eastern Cooperative Oncology Group

Phase 2 Terminated
6 enrolled 7 charts
NCT01028716 2023-01-23

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase 2 Terminated
46 enrolled 18 charts
NCT01805037 2021-09-01

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Northwestern University

Phase 1/2 Terminated
20 enrolled 17 charts
NCT00003056 2021-05-06

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Takeda

Phase 3 Terminated
105 enrolled
NCT01678443 2021-04-02

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 1 Terminated
2 enrolled 6 charts
NCT01643603 2020-12-17

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
5 enrolled
NCT02991898 2020-09-29

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
3 enrolled 17 charts
NCT00726830 2020-09-24

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

M.D. Anderson Cancer Center

Phase NA Terminated
1 enrolled 3 charts
NCT01609816 2020-03-16

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
8 enrolled
NCT02145039 2019-12-26

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
2 enrolled 11 charts
NCT00651716 2019-11-15

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Vanderbilt-Ingram Cancer Center

Terminated
150 enrolled
NCT01159067 2019-06-18

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

City of Hope Medical Center

Phase 2 Terminated
1 enrolled 4 charts
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT00904514 2018-10-05

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

National Institutes of Health Clinical Center (CC)

Terminated
241 enrolled
NCT02728700 2018-09-12

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Stanford University

Phase 1 Terminated
1 enrolled
NCT00949052 2018-08-16

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Vanderbilt-Ingram Cancer Center

Terminated
1,000 enrolled
NCT00617929 2017-12-28

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
12 enrolled 12 charts
NCT00005993 2017-11-29

Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
NCT00290628 2017-11-29

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
43 enrolled
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT01076270 2017-06-28

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase NA Terminated
1 enrolled 7 charts
NCT00719849 2017-06-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
13 enrolled 24 charts
NCT00324324 2017-05-09

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

OHSU Knight Cancer Institute

Phase 3 Terminated
240 enrolled